Depression and Anxiety Trial, Recruiting NCT04004169 Sponsor: Andrew Krystal Condition: Depression and Anxiety
Back to Depression And Anxiety

Depression and Anxiety Trial, Recruiting

NCT04004169
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 22 and 70 years old
  • You have been diagnosed with Major Depressive Disorder (MDD) without psychosis, confirmed through a formal structured interview
  • Your current episode of depression has lasted 2 years or longer and has not responded to treatment — specifically, you have tried at least 4 adequate treatments (including electroconvulsive therapy/ECT), at least 3 different types of medications, at least one add-on medication strategy, and psychotherapy
  • You tried ECT but it either did not provide lasting relief (after 2 attempts to stop ECT it kept coming back) or you had to stop because the side effects were too difficult to tolerate
  • Your depression symptoms score above 26 on a standard depression rating scale (called the MADRS) at both your screening and baseline appointments
  • Your depression symptoms show some natural day-to-day variation, measured by a brief mood rating taken 3 times a day for 3 days (confirm with trial site)
  • If you are already taking psychiatric medications, you have not changed them in the 4 weeks before joining and agree not to change them during the study
  • You are willing and able to undergo a brain recording and stimulation procedure
  • You are willing and able to come to multiple research visits and follow a research routine at home
  • You are willing and able to give informed consent
  • You can speak and read English

Who may not be able to join:

  • You have been diagnosed with another major psychiatric condition such as a psychotic disorder, eating disorder, panic disorder, PTSD, bipolar disorder, OCD, a tic disorder, or another significant psychiatric disorder (note: generalized anxiety disorder alongside MDD may be acceptable — confirm with trial site)
  • Your main diagnosis during your current depressive episode is generalized anxiety disorder rather than MDD
  • You are currently having thoughts of suicide with a specific intent and plan
  • You have been hospitalized for a suicide attempt in the past 2 years
  • You have had problems with alcohol or substance misuse (other than caffeine) in the past 6 months
  • You have a personality disorder that the study team believes could affect your safety or ability to follow the study requirements
  • You have fibromyalgia or chronic fatigue syndrome
  • You currently need to take narcotic (opioid) pain medications on an ongoing basis
  • You have a history of traumatic brain injury, a neurological condition, or a developmental delay
  • You have a history of seizures
  • A recent brain MRI (within the past year) showed significant abnormalities
  • You have previously had brain surgery to remove or destroy tissue, or you already have a deep brain stimulation device or another implanted brain stimulation device
  • You have any implanted hardware in your body that is not compatible with MRI or with the study equipment
  • You have serious medical conditions that would increase the risks of surgery — for example, severe diabetes, major organ failure, a history of bleeding stroke, need for blood-thinning medications (other than aspirin), active infection, a brain lesion, high pressure in the brain, a recent stroke, a brain aneurysm, retinal detachment, unstable heart disease, a weakened immune system, or cancer with a life expectancy of less than 5 years
  • You are unable to safely stop blood-thinning or anti-clotting medications for surgery (your doctors would need to discuss this carefully — confirm with trial site)
  • You have a blood clotting disorder, unless reviewed and cleared by a blood specialist
  • You have allergies or known reactions to materials used in the NeuroPace RNS® device, such as titanium, silicone, or stainless steel
  • You live alone with no one available to support you after your hospital stay
  • You are unable to attend the required follow-up visits
  • You are pregnant, planning to become pregnant, or currently breastfeeding
  • You are unable to speak or read English
  • You are unable to give informed consent
  • You have significant memory or thinking difficulties or dementia (based on a standard cognitive test score below 25)
  • You are likely to need ECT treatment during the course of the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Andrew Krystal, MD, MS, University of California, San Francisco

Phone: 415-476-7439

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Andrew Krystal
Registry
ClinicalTrials.gov
Start date
18 July 2019
Est. completion
28 June 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

change in MADRS score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov